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ABSTRACT
Macroautophagy/autophagy is a cellular degradation pathway that delivers cytoplasmic material to
lysosomes via double-membrane organelles called autophagosomes. Lipidation of ubiquitin-like LC3/
GABARAP proteins on the autophagosome membrane is important for autophagy. The cysteine
protease ATG4 executes 2 LC3/GABARAP processing events: priming of newly synthesized pro-LC3/
GABARAP to enable subsequent lipidation, and delipidation/deconjugation of lipidated LC3/
GABARAP (the exact purpose of which is unclear in mammals). Four ATG4 isoforms (ATG4A to
ATG4D) exist in mammals; however, the functional redundancy of these proteins in cells is poorly
understood. Here we show that human HAP1 and HeLa cells lacking ATG4B exhibit a severe but
incomplete defect in LC3/GABARAP processing and autophagy. By further genetic depletion of ATG4
isoforms using CRISPR-Cas9 and siRNA we uncover that ATG4A, ATG4C and ATGD all contribute to
residual priming activity, which is sufficient to enable lipidation of endogenous GABARAPL1 on
autophagic structures. We also demonstrate that expressing high levels of pre-primed LC3B in ATG4-
deficient cells can rescue a defect in autophagic degradation of the cargo receptor SQSTM1/p62,
suggesting that delipidation by human ATG4 is not essential for autophagosome formation and
fusion with lysosomes. Overall, our study provides a comprehensive characterization of ATG4 isoform
function during autophagy in human cells.
Abbreviations: Atg: autophagy-related; baf A1: bafilomycin A1; CASP3: caspase 3; CLEM: correlative light
and electron microscopy; CMV: cytomegalovirus; CRISPR: clustered regularly interspaced short palindro-
mic repeats; DKO: double knockout; EGFP: enhanced green fluorescent protein; GABARAP: GABA type A
receptor-associated protein; GABARAPL1: GABA type A receptor-associated protein like 1; GABARAPL2:
GABA type A receptor-associated protein like 2; GFP: green fluorescent protein; HB: homogenization
buffer; KO: knockout; LAMP1: lysosomal associated membrane protein 1; LIR: LC3 interacting region;
MAP1LC3/LC3: microtubule-associated protein 1 light chain 3; MFN2: mitofusin 2; N.A.: numerical
aperture; NEM: N-ethylmaleimide; PDHA1: pyruvate dehydrogenase E1 alpha 1 subunit; PLD: phospho-
lipase D; PE: phosphatidylethanolamine; RLUC: Renilla luciferase; SQSTM1: sequestosome 1; TEM: trans-
mission electron microscopy; TKO: triple knockout; ULK1: unc-51 like autophagy activating kinase 1; VCL:
vinculin; WT: wild-type
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Introduction
Macroautophagy (hereafter autophagy) is a conserved process
in eukaryotic cells that delivers cytoplasmic material including
protein aggregates and damaged organelles to lysosomes for
degradation. It involves the formation of a cup-shaped mem-
brane (phagophore) that expands to surround the cargo to be
degraded. Once fully closed, the resulting double-membrane
organelle (autophagosome) undergoes fusion with endosomes
and lysosomes. This eventually leads to degradation of inner
autophagosome membrane and its contents, allowing recy-
cling of macromolecules within. Autophagy serves to mobilize
nutrients during starvation, as well as being important for
pathogen defense, cellular remodeling and proteostasis [1,2].
The genes that regulate autophagy, termed autophagy-
related (Atg) genes, were first identified in yeast [3,4], leading
to functional studies into the molecular mechanisms of Atg
proteins. These discoveries revealed that most Atg proteins
cluster into 1 of 5 ‘core machinery’ components that act in
largely consecutive steps during autophagosome formation:
the ULK protein kinase complex, BECN1/beclin1-PIK3C3/
Vps34 lipid kinase complex, the Atg9 trafficking system, and
the Atg12–Atg5 and Atg8–PE ubiquitin-like conjugation sys-
tems. In the latter, the small ubiquitin-like protein Atg8 (LC3/
GABARAP in mammals) is covalently conjugated to phos-
pholipids such as phosphatidylethanolamine (PE) on the pha-
gophore membrane in a reaction mechanism similar to
ubiquitin conjugation [5]. This lipidation reaction is catalysed
by E1-like activating enzyme Atg7, E2-like conjugating
enzyme Atg3 and enhanced by the E3-like Atg12–Atg5 con-
jugate formed in the preceding reaction [6]. Lipidation of
Atg8 is essential for autophagy because it contributes to
autophagosome biogenesis [7], as well as recruitment of spe-
cific autophagy cargo via cargo receptors that bind directly to
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Atg8 such as the ubiquitin-binding protein SQSTM1/p62 [8].
The cysteine protease Atg4 is thought to regulate Atg8 lipida-
tion through 2 processing steps. First, newly synthesized Atg8
undergoes priming/activation by proteolytic cleavage of its
C-terminus to expose a specific glycine residue that is subse-
quently targeted to PE during lipidation [9]. Second, Atg4 can
hydrolyze the amide linkage between Atg8 and PE in
a delipidation/deconjugation step that recycles free Atg8. In
yeast, this delipidation reaction is proposed to be important
for full autophagic flux and autophagosome formation, while
additionally preventing the mislocalization of lipidated LC3 to
other membranes in the cell [10–12]. Whether the role of
delipidation is conserved in mammalian cells remains to be
determined.
Mammalian genomes encode multiple isoforms of Atg4 and
Atg8. The Atg8 proteins are divided into two subfamilies: LC3
(MAP1LC3A, B, B2 and C) and GABARAP (GABARAP,
GABARAPL1 and GABARAPL2). Recently, LC3/GABARAP
has been implicated in inner autophagosome membrane degra-
dation [13], and in a separate study these proteins were impli-
cated in autophagosome-lysosome fusion [14]. This is in
contrast to an earlier study that proposed the different subfami-
lies to play essential and distinct roles in phagophore elongation
and closure [15]. Despite growing interest in LC3/GABARAP
isoform function, it remains unclear which of the mammalian
ATG4 isoforms (ATG4A, B, C and D) are responsible for LC3/
GABARAP processing and autophagy in cells. ATG4B is con-
sidered to be the main isoform since studies in vitro show that it
has the most activity and broadest specificity towards cleaving
different isoforms of synthetic tagged LC3/GABARAP con-
structs [16]. ATG4A has been shown to be capable of processing
GABARAP subfamily isoforms [17], but with a reduced activity
compared to ATG4B [16]. In contrast, ATG4C and ATG4D
exhibit almost no in vitro activity [16], but the activity of
ATG4D in cells might be enhanced through N-terminal cleavage
mediated by the apoptosis-regulating protease CASP3/caspase-3
[18]. Althoughmice lacking ATG4B show reduced processing of
murine LC3/GABARAP orthologs, they survive to adulthood
with a balance disorder suggesting they suffer from an impair-
ment rather than complete defect in autophagy [19]. This is in
contrast to ATG3-deficient mice which completely lack LC3/
GABARAP lipidation and die from starvation shortly after birth
[20]. However it is not knownwhich of the other ATG4 isoforms
could contribute to LC3/GABARAP processing in the absence of
ATG4B.
In this study, we performed a detailed characterization of
human cells lacking ATG4B to determine its role in autop-
hagy. We show that loss of ATG4B causes severe defects in
autophagy and LC3/GABARAP processing, however the
remaining ATG4 activity is sufficient for residual lipidation
and autophagosome localization of GABARAP subfamily iso-
forms. By further depletion of ATG4 isoforms, we discover
that ATG4A, ATG4C and ATGD all contribute to the remain-
ing processing activity and thus show overlapping redundancy
in cells. We also investigate roles of ATG4-mediated delipida-
tion by rescuing ATG4-deficient cells with high-level expres-
sion of pre-primed LC3/GABARAP, uncovering that ATG4-
mediated delipidation is not essential for autophagosome for-
mation or lysosome fusion.
Results
ATG4B is required for LC3B lipidation but not GABARAPL1
and GABARAPL2 lipidation
In order to dissect the function of ATG4B in autophagy, we
obtained human HAP1 cells lacking ATG4B. We previously
reported that these cells exhibit a complete absence of endo-
genous LC3B puncta as detected by immunofluorescence, in
contrast to the same cells rescued with ectopic expression of
wild-type ATG4B (but not catalytic-inactive C74S mutant)
that showed a strong accumulation of LC3B puncta when co-
treated with the autophagy inducer Torin1 and lysosome
inhibitor bafilomycin A1 (baf A1) [21]. This observation
prompted us to determine the mechanism behind loss of
LC3B puncta in ATG4B-deficient cells, and to explore
whether this phenotype was reproducible in a more widely
characterized human autophagy cell model. To this end, we
generated HeLa cells lacking ATG4B using CRISPR-Cas9,
with complete loss of ATG4B protein confirmed by western
blotting (Figure S1A). Indeed, ATG4B KO HeLa cells showed
an absence of LC3B puncta both basally and in response to
treatment with Torin1 and baf A1 (Figure 1(a)), in contrast to
wild-type (control) HeLa cells, which exhibited bright puncta
of endogenous LC3B that accumulated and colocalized with
the lysosome marker LAMP1 in response to treatment.
To investigate the overall effect of ATG4B loss on the
processing of endogenous LC3B, we treated ATG4B KO and
wild-type counterpart (control) HAP1 and HeLa cells with
starvation medium (EBSS) or Torin1 in combination with baf
A1 to assess autophagic flux, and analyzed cell lysates by
western blotting. As shown in Figure 1(b), treatment of wild-
type cells with baf A1 resulted in expected increased levels of
the lower band of LC3B corresponding to the lipidated form,
LC3B-II (LC3B–PE). There was a further increase in these
lipidation levels upon co-treatment with Torin1, consistent
with an increase in autophagic flux. Interestingly, starvation
did not appear to stimulate further lipidation of LC3B, possi-
bly since it was less efficient than Torin1 at causing de-
phosphorylation of the upstream kinase ULK1 at its inhibitory
phosphorylation site (Ser757) [22] (Figure 1(b)). Strikingly, in
ATG4B KO cells we only observed a single specific band of
LC3B that showed a similar migration to LC3B-II (Figure 1
(b)). Note that the band marked by an asterisk at the height of
LC3B-I in HeLa ATG4B KO cells was not detected using other
LC3B antibodies and thus was deemed to be non-specific (see
Figure S1B). The specific band seen in ATG4B KO cells did
not accumulate further in response to Torin1 or baf A1
treatment, despite Torin1 treatment efficiently leading to
dephosphorylation of ULK1. Cells lacking ATG4B also
showed an accumulation of SQSTM1 and a reduced clearance
of this protein upon Torin1 treatment, suggestive of an autop-
hagy defect (Figure 1(b)). As human pro-LC3B was recently
described to have a similar migration rate to lipidated LC3B
by SDS-PAGE [23], we suspected that the single lower band of
LC3B might correspond to pro-LC3B and thus potentially
explain the impairment in autophagy.
In order to distinguish between endogenous pro-LC3B and
LC3B-II, we devised an assay in which lysates of cells treated
2 A. AGROTIS ET AL.
Figure 1. ATG4B is required for LC3B lipidation but not GABARAP isoform lipidation. (a) Localization of endogenous LC3B and LAMP1 in HeLa control and ATG4B KO
cells treated for 3 h with DMSO or 250 nM Torin1 + 10 nM bafilomycin A1 (baf A1) revealed by immunocytochemistry. Scale bar: 10 µm. Quantification of LC3B
puncta per cell shown on right hand side. n = 15 randomly-selected cells per condition. **** P ≤ 0.0001, *** P ≤ 0.001, n.s. (not significant) P > 0.05 (Sidak’s multiple
comparison test). (b) Western blotting of lysates from HAP1 and HeLa control and ATG4B KO cells treated for 3 h with either 250 nM Torin1 or EBSS in the presence or
absence of 10 nM baf A1. Lysis was performed in the presence of 20 mM NEM (N-ethylmaleimide) since this was required to stabilize lipidated GABARAP and
GABARAPL1 (see also Figure S1E). Background band detected by LC3B antibody is indicated with an asterisk (see also Figure S1B). (c) Diagram showing bonds
present at the C terminus of pro- and lipidated (PE-conjugated) LC3/GABARAP that can be cleaved by ATG4B or PLD in vitro (not to scale). This principle provides the
basis for distinguishing between the pro-LC3/GABARAP and lipidated LC3/GABARAP by western blot. (d) PLD bandshift assay performed on HeLa control or ATG4B KO
cells treated for 3 h with 250 nM Torin1 + 10 nM baf A1 and lysed in PLD assay buffer with or without 20 mM NEM. Lysates were subject to in vitro treatment with
purified PLD or GST-ATG4B prior to western blotting.
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with Torin1 and baf A1 were subject to treatment with
recombinant ATG4B or PLD (phospholipase D) prior to
western blot analysis. Because PLD cleaves a bond that is
only present in lipidated forms of LC3/GABARAP [24],
a migration shift upon PLD treatment is indicative of the
presence of the lipidated species (Figure 1(c)). As a control,
recombinant ATG4B can cleave both pro- and lipidated LC3/
GABARAP revealing any potential migration shift from both
of these forms (Figure 1(c)). The predominant LC3B band in
HeLa ATG4B KO cells was completely resistant to PLD treat-
ment but underwent a migratory shift with ATG4B treatment,
in contrast to the corresponding band that was sensitive to
both PLD and ATG4B in wild-type cells (Figure 1(d)). This
demonstrates that ATG4B KO cells accumulate pro-LC3B
rather than LC3B-II, an observation that was also confirmed
in HAP1 cells treated with baf A1 (Figure S1C). Therefore,
ATG4B is essential for the priming of pro-LC3B and its
subsequent lipidation, explaining the absence of LC3B puncta
in ATG4B KO cells.
We could also determine the effect of ATG4B loss on
GABARAP subfamily isoforms in the same set of experi-
ments, using specific antibodies to detect endogenous
GABARAP, GABARAPL1 and GABARAPL2. We observed
that total levels of free GABARAP and GABARAPL1 were
dramatically reduced in ATG4B KO cells compared to wild-
type cells (Figure 1(b)), consistent with a recently discovered
role of the C-terminal LC3 interacting region (LIR) of murine
ATG4B in stabilizing the non-lipidated forms of these pro-
teins and reducing their proteasomal degradation [25]. Our
data suggest this function is conserved in human cells, since
proteasome inhibition by treatment with the compound
MG132 could also raise GABARAP protein levels in ATG4B
KO HeLa cells (Figure S1D). In respect to lipidation, we
could observe an accumulation of lower bands of all
GABARAP isoforms in wild-type (control) HAP1 and HeLa
cells in response to Torin1 and baf A1 treatment (Figure 1
(b)), consistent with all of these proteins being involved in
autophagy. Despite their levels generally being reduced in
ATG4B KO cells, the lower bands of GABARAPL1 and
GABARAPL2 still accumulated in response to treatment. To
determine whether these lower bands corresponded to the
lipidated forms of GABARAP proteins, we also detected
endogenous GABARAP isoforms in PLD assay samples
(Figure 1(d)). Indeed, the lower bands of GABARAPL1 and
GABARAPL2 were sensitive to PLD treatment in both control
and ATG4B KO HeLa cells, confirming that they corre-
sponded to the lipidated forms of the proteins. This result
could only be determined when the assay buffer contained the
irreversible ATG4 inhibitor N-ethylmaleimide (NEM) [9]
otherwise the lower band was absent or reduced by heat
treatment alone presumably due to processing by endogenous
ATG4 activity in the lysate. In fact, it proved essential to
include NEM in the lysis buffer for all western blot experi-
ments assessing GABARAP and GABARAPL1 lipidation,
since the lipidated forms of these proteins were particularly
unstable in wild-type cell lysates lacking NEM (Figure S1E).
Collectively, our data show that human cells lacking
ATG4B fail to form lipidated LC3B due to a defect in the
initial priming/activation of LC3B, and thus accumulate
unprocessed pro-LC3B. However the presence of lipidated
GABARAPL1 and GABARAPL2 in ATG4B KO cells suggests
that these isoforms can be processed independently of
ATG4B.
Loss of ATG4B leads to a severe but incomplete defect in
LC3/GABARAP priming
To determine whether differences in LC3/GABARAP lipida-
tion seen between ATG4B KO and wild-type cells could be
explained by impaired priming activity, we generated con-
structs encoding all LC3/GABARAP isoforms tagged at the
N terminus with the 3xFLAG epitope and at the C terminus
with GFP (Figure 2(a)). These constructs undergo a large
molecular weight shift that is easily detectable by western
blotting when cleaved at the C terminus by ATG4 in cells.
This approach was necessary for comparing the effect of
ATG4B on processing of each individual LC3/GABARAP iso-
form, since some commercial antibodies cannot distinguish
between endogenous isoforms that are very similar in peptide
sequence. As a positive control we expressed 3xFLAG-LC3B-
G120 that lacks a C-terminal pro-peptide and therefore cor-
responds to primed LC3B, and as a negative control we
expressed 3xFLAG-LC3B-G120A-GFP that cannot be primed
due to mutation of its active glycine residue to alanine. As
seen in Figure 2(b), all LC3/GABARAP isoforms were pro-
cessed in an ATG4B-dependent manner since efficient prim-
ing occurred in wild-type cells but was abolished or reduced
in cells lacking ATG4B. These constructs appeared to undergo
non-specific cleavage within the GFP sequence (band marked
with asterisk) but nonetheless ATG4-dependent cleavage
could clearly be distinguished by the presence of bands in
the 15–25 kDa range (Figure 2(b)). Of note, it was possible to
detect slight processing of GABARAPL2 and an even smaller
amount of LC3A processing in cells lacking ATG4B. Very
small amounts of processed GABARAP and GABARAPL1
could also be observed in ATG4B KO cells, but higher con-
trast western blot images were required to detect this proces-
sing (Figure 2(b)), which is possibly explained by the relative
instability of these isoforms due to enhanced proteasomal
degradation when ATG4B is missing [25].
To characterize the relative SDS-PAGE migration of each
form (pro vs. -I vs. -II) of LC3/GABARAP isoform, and as an
alternative approach to investigate LC3/GABARAP processing
by ATG4B without relying on C-terminal tags, we also gen-
erated full-length LC3/GABARAP constructs tagged at the
N terminus with 3xFLAG with their native C-termini (WT),
uncleavable mutants (GA) and mutants corresponding to the
primed form with their active glycine exposed (G) (Figure 2
(c)). When these constructs were expressed in wild-type HeLa
cells treated with Torin1 and baf A1, both WT and G mutants
underwent similar levels of lipidation (formation of band with
lower apparent molecular weight) suggesting that priming of
WT constructs occurred normally prior to their lipidation and
did not dramatically affect the level of lipidation (Figure 2(d),
S2). However, in ATG4B KO cells, WT constructs were pre-
sent as bands with similar motility to GA mutants suggesting
they were mainly unprocessed (Figure 2(d), S2). In these cells,
small amounts of LC3A, GABARAP and GABARAPL1
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Figure 2. Loss of ATG4B leads to a severe but incomplete defect in LC3/GABARAP priming. (a) Schematic of N-terminal 3xFLAG C-terminal GFP double-tagged LC3/
GABARAP constructs used in Figure 2(b) (not to scale). Cleavage site targeted by ATG4 in cells is indicated, resulting in formation of primed/activated 3xFLAG-LC3/
GABARAP-I. The primed form can then undergo lipidation in cells to form 3xFLAG-LC3/GABARAP-II. (b) Western blotting of lysates from HeLa control and ATG4B KO cells
transiently transfected with the indicated 3xFLAG-LC3/GABARAP-GFP, positive (3xFLAG-LC3B-G120) and negative (3xFLAG-LC3B-G120A-GFP) control constructs. At 24 h
post-transfection, cells were treated for 3 h with 250 nM Torin1 + 10 nM baf A1 prior to lysis. Specific cleaved and lipidated products arising from ATG4 activity are
indicated as 3xFLAG-LC3/GABARAP-I/II. The band marked with an asterisk corresponds to a non-specific cleavage product. (c) Schematic of N-terminal 3xFLAG-tagged
LC3/GABARAP constructs used in Figure 2(d) (not to scale). Cleavage site in wild-type (WT) constructs targeted by ATG4 in cells is indicated, resulting in formation of
primed 3xFLAG-LC3/GABARAP-I. To bypass cleavage, 3xFLAG-LC3/GABARAP G constructs were expressed that lack the C-terminal pro-peptide/residue. The primed form
can then undergo lipidation in cells to form 3xFLAG-LC3/GABARAP-II. Mutation of the active glycine residue to alanine in 3xFLAG-LC3/GABARAP GA blocks priming,
therefore this construct corresponds to the pro- form of the protein and cannot undergo conversion to 3xFLAG-LC3/GABARAP-I or further conversion to 3xFLAG-LC3/
GABARAP-II. (d) Western blotting of lysates from HeLa control and ATG4B KO cells transiently transfected with indicated 3xFLAG-LC3/GABARAPwild-type (WT), primed (G)
and uncleavable (GA) constructs. At 24 h post-transfection, cells were treated for 3 h with 250 nM Torin1 + 10 nM baf A1 prior to lysis. Anti-FLAG antibody was used to
detect the expressed constructs. Presented as a comparison between control and ATG4B KO cells for each individual LC3/GABARAP, see also Figure S2 for original blots.
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lipidation were observed at high contrast for WT constructs,
but at reduced levels compared to G mutants (Figure 2(d)). In
this particular experiment, it was difficult to resolve the dif-
ferent forms of 3xFLAG-GABARAPL2.
Altogether, these results suggest that most LC3 subfamily
isoforms absolutely require ATG4B for priming (LC3B,
LC3B2 and LC3C). Conversely, priming of other LC3/
GABARAP isoforms (LC3A and GABARAP subfamily) can
occur in ATG4B-deficient cells but is markedly reduced in
efficiency, thus limiting the amount of lipidated LC3/
GABARAP that can accumulate.
GABARAPL1 can localize to autophagic structures in cells
lacking ATG4B
Following the observation of lipidation of GABARAP iso-
forms in response to autophagy stimulation in both wild-
type and ATG4B-deficient cells, we decided to assess the
subcellular localization of endogenous GABARAPL1 using
a validated isoform-specific antibody [26]. We found that in
both ATG4B KO HAP1 and HeLa cells, GABARAPL1 loca-
lized to distinct puncta that accumulated in an autophagy-
dependent manner and colocalized with LAMP1 upon baf A1
treatment (Figure 3(a,b)), in stark contrast to the absence of
LC3B puncta in ATG4B KO cells under the same conditions
(Figure 1(a)). This is consistent with increased GABARAPL1
lipidation levels in response to treatment as observed by
western blot (Figure 1(b)). Although in wild-type cells
GABARAPL1 puncta were less pronounced due to the higher
cytoplasmic levels of free GABARAPL1 (Figure 3(a,b)), quan-
titative image analysis revealed that both HeLa control and
ATG4B KO cells formed similar numbers of basal and treat-
ment-induced GABARAPL1 puncta (Figure 3(a)). To investi-
gate whether these puncta truly represent autophagosomes,
we performed correlative light and electron microscopy
(CLEM) of wild-type and ATG4B KO HAP1 cells stably
expressing GFP-GABARAPL1 (Figure 3(c)). We first con-
firmed that stably expressed GFP-GABARAPL1 WT (posses-
sing its wild-type C terminus) could indeed localize to puncta
in response to Torin1 and baf A1 treatment in both wild-type
and ATG4B KO HAP1 cells (Figure S3). When GFP-
GABARAPL1 puncta identified by light microscopy were
located in transmission electron micrographs, they were seen
to correspond to autophagic structures in both wild-type and
ATG4B KO cells (Figure 3(c)). Altogether this shows that the
remaining priming activity in ATG4B KO cells is sufficient to
allow GABARAPL1 to localize to autophagic structures.
Loss of ATG4B impairs autophagosome formation and
SQSTM1 delivery to lysosomes
Having determined the impact of ATG4B loss on LC3/
GABARAP priming and lipidation, we next decided to deter-
mine how this affects overall autophagosome formation. To
achieve this, we performed transmission electron microscopy
(TEM), a technique that allows the quantification of autopha-
gosomes based on their distinct ultrastructure without relying
on marker proteins. Using this method, autophagic structures
can be identified by their characteristic morphology of
cytoplasmic material sequestered within a double or multi-
membrane compartments [27]. In untreated HAP1 control
and ATG4B KO cells, autophagic structures were rarely
observed (Figure 4(a,b)). Upon treatment with baf A1 and
Torin1, a large number of autophagosomes was readily
observed in control cells, occupying 2.66 ± 0.426% (mean ±
SEM) of the total cytoplasm area. In treated ATG4B KO cells
however, cytoplasm area occupied by autophagic structures
was significantly reduced (0.677 ± 0.290%) (Figure 4(a,b)).
However, autophagic structures were still observed in treated
ATG4B-deficient cells and the number of structures per cell
was not significantly reduced. These structures had an altered
morphology, being significantly smaller than those seen in
control cells. Autophagosomes in control cells were on aver-
age 655 ± 12.8 nm in diameter while structures in ATG4B KO
cells had a mean diameter of 578 ± 17.7 nm (Figure 4(a,b)).
Collectively, these data show that ATG4B is important for
proper autophagosome formation but not absolutely required
for the presence of autophagic structures.
As an additional functional indicator of autophagic flux, we
monitored the delivery of endogenous SQSTM1 to lysosomes
marked by LAMP1 using immunofluorescence (Figure 5(a,b)).
In wild-type HeLa cells, small SQSTM1 puncta accumulated
within LAMP1-positive structures upon baf A1 treatment, con-
sistent with a blockage in the autophagic degradation of
SQSTM1 within autolysosomes. This accumulation was mark-
edly increased in the additional presence of Torin1, consistent
with an increase in delivery of SQSTM1 to lysosomes upon
autophagic stimulation (Figure 5(a)). However in HeLa ATG4B
KO cells, the recruitment of SQSTM1 to lysosomes upon Torin1
+ baf A1 treatment was dramatically reduced (Figure 5(a,b)) and
fewer small SQSTM1 puncta were observed under all treatment
conditions (Figure 5(a)), signifying a diminished ability for these
cells to recruit SQSTM1 to autophagosomes. Large SQSTM1
puncta that were typically negative for LAMP1 staining were
observed in a subset of HeLa ATG4B KO cells under all treat-
ment conditions (Figure 5(a), white arrowheads), likely corre-
sponding to SQSTM1-positive protein aggregates that have
previously been shown to accumulate in HeLa cells when autop-
hagy is impaired [28]. We observed similar results in HAP1 cells
during starvation by western blot (Figure S4A) and in response
to compound treatment by immunocytochemistry (Figure
S4B). These results are consistent with the SQSTM1 accumula-
tion and reduced Torin1-induced degradation observed in
ATG4B KO cells by western blot (Figure 1(b)). Altogether, loss
of ATG4B impairs both the formation of autophagosomes and
the recruitment of SQSTM1 to autophagosomes.
Overexpression of pre-primed LC3B rescues autophagy
defects in ATG4B KO cells
Next we decided to determine whether ATG4B plays an essential
role in the autophagy pathway after executing pro-LC3B prim-
ing. To achieve this, we used a mutant form of LC3B that
terminates at the C-terminal active glycine (G120) and thus
bypasses the ATG4-dependent priming step and corresponds
to primed/activated LC3B. Comparing the effects on autophagy
of expression of LC3B-G120 in wild-type versusATG4BKO cells
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Figure 3. GABARAPL1 can localize to autophagic structures in the absence of ATG4B. (a) Immunocytochemistry of endogenous GABARAPL1 and LAMP1 in HeLa
control or ATG4B KO cells, treated with DMSO or 250 nM Torin1 + 10 nM baf A1 for 3 h prior to fixation. Yellow boxes show region-of-interest in the Torin1 + baf A1
treated condition that is enlarged in the panels below. Scale bar: 10 µm. Quantification of GABARAPL1 puncta per cell shown on right hand side. n = 15 randomly-
selected cells per condition. **** P ≤ 0.0001, n.s. (not significant) P > 0.05 (Sidak’s multiple comparison test). (b) Immunocytochemistry as described in Figure 3(a), for
HAP1 control and ATG4B KO cells. (c) CLEM of GFP-GABARAPL1 WT stably expressed in in HAP1 control and ATG4B KO cells treated for 3 h with 250 nM
Torin1 + 10 nM baf A1 prior to fixation. Yellow arrowheads indicate GFP-positive autophagic structures. Confocal microscopy image corresponds to a single confocal
slice. Scale bar: 1 µm.
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should therefore reveal any autophagy defect caused specifically
by the loss of ATG4B in steps subsequent to priming.
When expressed in both wild-type and ATG4B KO HAP1
cells, 3xFLAG-LC3B-G120 underwent lipidation in an autop-
hagy-dependent manner as determined by western blot, show-
ing that bypassing priming can restore LC3B lipidation and
flux in ATG4B-deficient cells (Figure 6(a). When the stably-
expressed GFP-tagged version of this construct was examined
by light microscopy, it was seen to localize to punctate struc-
tures that accumulated in a Torin1 and baf A1 treatment-
dependent manner in both wild-type and ATG4B KO
HeLa cells, in contrast to WT LC3B which could not form
puncta in ATG4B KO cells (Figure S5A). When both HeLa
(Figure 6(b)) and HAP1 cells (Figure S5B) stably expressing
GFP-LC3B-G120 were stained for endogenous SQSTM1, this
revealed that GFP puncta were positive for SQSTM1 in both
wild-type and ATG4B KO genetic backgrounds. Under baf A1-
treated conditions, these puncta also overlapped with LAMP1
staining (Figure 6(b), S5B). HeLa ATG4B KO cells expressing
GFP-LC3B-G120 showed an identical pattern of SQSTM1
lysosome delivery to control cells, because there was no sig-
nificant difference in the extent of SQSTM1 colocalization
with LAMP1 between the two cell lines, both in the absence
of treatment and when elevated in response to Torin1 + baf A1
treatment (Figure 6(c)). Therefore, GFP-LC3B-G120 expres-
sion in ATG4B KO cells could efficiently rescue the defect in
SQSTM1 delivery to lysosomes observed in untransduced cells
(Figure 5(a,b), S4B). When puncta of stably expressed GFP-LC
3B-G120 in HAP1 cells were examined by CLEM, they were
seen to correspond to autophagic structures in both wild-type
and ATG4B-deficient cells (Figure 6(d)), suggesting that
ATG4B is not required for the correct localization of LC3B
after priming has occurred.
Because ATG4-mediated delipidation has previously been
implicated in autophagosome closure, we next assessed
whether LC3B-positive vesicles formed in ATG4B-deficient
cells represent fully sealed structures using a protease protec-
tion assay (Figure S5C). In this assay, unpermeabilized cell
homogenates and an equivalent permeabilized sample are
subject to trypsin treatment followed by western blot analysis.
Proteins that are specifically protected from degradation in
the unpermeabilized sample but become sensitive to degrada-
tion in the presence of detergent are considered to be pro-
tected by membrane and thus localized within sealed vesicles
or organelles. This assay was able to distinguish between
proteins on the inside and outside of a sealed double-
membrane organelle, since the mitochondrial matrix protein
PDHA1 (pyruvate dehydrogenase E1 alpha 1 subunit) was
only efficiently degraded by trypsin in the presence of deter-
gent, while the cytosol-facing outer mitochondrial membrane
protein MFN2 (mitofusin 2) was degraded completely in both
presence and absence of detergent. The lysosome membrane
protein LAMP1 served as a loading control in this assay since
it was relatively resistant to trypsin. We found that a similar
fraction of transiently transfected 3xFLAG-LC3B-G120 was
resistant to trypsin degradation in the absence of detergent
in both HAP1 control and ATG4B KO cells treated with
Torin1 and baf A1 (Figure S5C). This suggests that closure
of autophagosomes is not impaired in the absence of ATG4B-
mediated LC3B delipidation.
Figure 4. Autophagosome formation defect in cells lacking ATG4B. (a) Representative transmission electron microscopy (TEM) images of areas of cytoplasm in HAP1
control and ATG4B KO cells treated for 3 h with DMSO or 250 nM Torin1 + 10 nM baf A1 prior to fixation and sample processing. Yellow arrowheads indicate
autophagic structures. Scale bar: 1 µm. (b) Quantitative TEM analysis of average cytoplasm area occupied by autophagic structures and average number of
autophagic structures per cell from experiments represented in Figure 4(a). Data points show mean from each experiment (n = 3 independent experiments). In each
experiment 8 randomly selected cell profiles were assessed per condition. *** P ≤ 0.001, ** P ≤ 0.01, n.s. (not significant) P > 0.05 (Sidak’s multiple comparison test).
For quantification of autophagosome size in terms of 2D area, data points represent individual autophagic structures measured from Torin1- and baf A1-treated
conditions pooled from 3 experiments (control n = 259, ATG4B KO n = 98). *** P ≤ 0.001, ** P ≤ 0.01 (Unpaired two-tailed t-test).
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Figure 5. Impaired autophagic delivery of SQSTM1 to lysosomes in cells lacking ATG4B. (a) Immunocytochemistry of endogenous SQSTM1 and LAMP1 in control and
ATG4B KO HeLa cells. Cells were treated for 3 h with DMSO or 250 nM Torin1 + 10 nM baf A1 prior to fixation and staining. White arrowheads indicate examples of
large SQSTM1 bodies in ATG4B KO cells that likely correspond to protein aggregates. Yellow boxes show region-of-interest in the Torin1 + baf A1 treated condition
that is enlarged in the panels below. Scale bar: 10 µm. (b) Assessment of colocalization between endogenous SQSTM1 and LAMP1 in HeLa control and ATG4B KO cells
using single-plane confocal images as represented in Figure 5(a). Bars indicate mean and error bars show standard deviation (n = 10 randomly-selected cells per
condition). **** P ≤ 0.0001, ** P ≤ 0.01, n.s. (not significant) P > 0.05 (Sidak’s multiple comparison test).
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Figure 6. Pre-primed LC3B is lipidated, localizes to autophagosomes, and can restore endogenous SQSTM1 turnover when expressed at high levels in ATG4B KO cells.
(a) HAP1 control and ATG4B KO cells transfected with 3xFLAG-LC3B-G120 using PEI were treated with combinations of DMSO or 250 nM Torin1 with or without 10 nM
baf A1 for 3 h prior to lysis and western blot analysis. (b) Immunocytochemistry of endogenous SQSTM1 and LAMP1 in HeLa control and ATG4B KO cells stably
expressing GFP-LC3B-G120 under control of the CMV promoter. Cells were treated for 3 h with combinations of DMSO or 250 nM Torin1 with or without 10 nM baf
A1 for 3 h prior to fixation and staining. Yellow boxes show region-of-interest in the Torin1 + baf A1 treated condition that is enlarged in the panels below. Scale bar:
10 µm. (c) Assessment of colocalization between endogenous SQSTM1 and LAMP1 in HeLa control and ATG4B KO cells stably expressing CMV promoter-driven GFP-
LC3B-G120 using single-plane confocal images as represented in Figure 6(b). Bars indicate mean and error bars show standard deviation (n = 10 randomly-selected
cells per condition). **** P ≤ 0.0001, n.s. (not significant) P > 0.05 (Sidak’s multiple comparison test). (d) CLEM of CMV-driven GFP-LC3B-G120 stably expressed in
HAP1 control and ATG4B KO cells. Cells were treated for 3 h with 250 nM Torin1 + 10 nM baf A1 prior to fixation. Upper panels show low magnification images with
a boxed region-of-interest (ROI); scale bar: 10 µm. Lower panels show enlarged ROI, with yellow arrowheads indicating GFP-positive autophagic structures; scale bar:
1 µm. Confocal microscopy image corresponds to a single confocal slice.
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Altogether, we find that bypassing pro-LC3B processing by
high expression of pre-primed LC3B rescues the autophagy
defect caused by loss of ATG4B and does not produce any
detectable abnormalities in LC3B localization, SQSTM1
degradation or autophagosome closure. This suggests that
ATG4B does not play an essential role in autophagy down-
stream of LC3/GABARAP priming.
Combined loss of ATG4A/4B does not block priming of
endogenous GABARAPL1/L2 or impair rescue of autophagy
by high-level overexpression of pre-primed LC3/GABARAP.
Following the discovery that ATG4B is not essential for
GABARAP subfamily priming or autophagy downstream of
LC3B priming, we next sought to identify the ATG4 isoforms
that compensate for loss of ATG4B. Because ATG4A is the
only other isoform known to efficiently process GABARAP
isoforms in vitro, this was the strongest candidate for being
responsible for GABARAP isoform function in ATG4B-
deficient cells. To address the role of ATG4A, we generated
multiple ATG4A/B double knockout (DKO) HeLa cell clones
using CRISPR-Cas9 and validated loss of ATG4A expression
by western blotting (Figure 7(a)). We found that when each of
these cell clones were treated with Torin1 and baf A1, they
could all still form lipidated GABARAPL1 and GABARAPL2
(Figure 7(a)) in addition to being able to form endogenous
GABARAPL1 puncta (Figure S6A), although the levels of
lipidation and puncta formation appeared to be slightly
reduced compared to ATG4B KO cells. When 3xFLAG-
GABARAPL2-GFP was expressed in HeLa ATG4A/B DKO
cells, it showed a marked reduction in priming compared to
ATG4B KO cells (Figure 7(b)). Altogether, this shows that
ATG4A is also involved in priming of GABARAPL1 and
GABARAPL2 but is not the sole ATG4 isoform responsible
for priming in ATG4B-deficient cells.
We confirmed by immunocytochemistry that ATG4A/B
DKO HeLa cells are impaired in SQSTM1 delivery to lysosomes
(Figure S6B), showing the same defect as ATG4B KO cells
(Figure 5(a)). Stable expression of both GFP-LC3B-G120 and
the equivalent bypass mutant of GABARAPL1 (GFP-
GABARAPL1-G116) in ATG4A/BDKOHeLa cells could rescue
SQSTM1 delivery to LAMP1-positive structures (Figure 7(c)).
Rescue of basal SQSTM1 turnover could also be observed in
these cells, since by western blot we could detect reduced levels
of SQSTM1 similar to those in control cells, in contrast to
untransduced ATG4A/B DKO cells which exhibited strongly
elevated basal levels of SQSTM1 (Figure 7(d)). This rescue of
basal SQSTM1 turnover was specifically due to bypass construct
expression, because knockdown of the bypass construct using
siRNA targeting GFP resulted in an elevation of SQSTM1
expression levels approaching that seen in untransduced
ATG4A/B DKO cells (Figure 7(d)). Further, rescue of SQSTM1
turnover by GFP-LC3B-G120 expression in ATG4A/B DKO
cells was dependent on LC3/GABARAP lipidation and autop-
hagy, since suppression of ATG3 and ATG7 in these cells led to
a strong accumulation of SQSTM1 similar to the effect of GFP
knockdown (Figure 7(e)). Collectively these data suggest that
both ATG4A and ATG4B are dispensable for basal and Torin1-
induced autophagy downstream of LC3/GABARAP priming.
We also separately generated HeLa ATG4A/B DKO cells
stably expressing GFP-LC3B-G120 or GFP-GABARAPL1
under control of a weak (PGK) promoter, to determine
whether expressing bypass mutants at lower levels would be
sufficient to rescue autophagy (Figure S7A). These cells could
form GFP puncta with the expected localization pattern
(Figure S7B), however they were notably less efficient at
reducing basal SQSTM1 level (Figure S7A) and rescuing
SQSTM1 delivery to lysosomes (Figure S8) compared to
equivalent ATG4A/B DKO cells expressing higher levels of
GFP-LC3B-G120 under control of the CMV promoter. These
results argue that the supply of primed LC3/GABARAP (i.e.
through recycling) might be a stronger requirement for autop-
hagy than ATG4 delipidation activity per se. Establishing
whether delipidation by ATG4 isoforms is necessary for func-
tional aspects of autophagy beyond regulating the level of
primed LC3/GABARAP (e.g. autophagosome-lysosome
fusion) requires a model system in which primed LC3/
GABARAP supply is plentiful. Therefore, we continued char-
acterizing ATG4-deficient cells expressing CMV promoter-
driven levels of bypass mutants for the remainder of our
study.
ATG4C and ATG4D both additionally contribute to GABARAP
isoform priming and lipidation independent of CASP3
expression.
Next, to identify the ATG4 isoforms responsible for residual
GABARAP isoform priming in ATG4A/B DKO cells, we used
RNAi to deplete combinations of ATG4C and ATG4D in
different HeLa cell lines treated with Torin1 and baf A1 to
induce GABARAP isoform lipidation. As seen in Figure 8(a),
RNAi-mediated suppression of ATG4C and ATG4D expres-
sion in HeLa ATG4A/B DKO cells was sufficient to comple-
tely block lipidation of GABARAPL1 and GABARAPL2
compared to control RNAi. In these cells, loss of ATG4D
alone produced a stronger inhibition of GABARAPL1/L2
lipidation compared to ATG4C loss, suggesting that ATG4D
was the main isoform involved in residual priming of these
GABARAP isoforms. Nonetheless, the observation that loss of
both ATG4C and ATG4D produced a complete inhibition of
lipidation suggests a partial involvement of ATG4C in
GABARAPL1/L2 priming. Importantly, these effects could
not be observed in HeLa cells lacking ATG4B alone, confirm-
ing that ATG4A is also involved in endogenous GABARAPL1
and GABARAPL2 priming. We confirmed these findings by
knockdown of ATG4C and ATG4D in HeLa ATG4A/B DKO
cells prior to immunostaining for endogenous GABARAPL1
(Figure 8(b)). This revealed that additional loss of ATG4C
and ATG4D blocked the formation of small perinuclear
GABARAPL1-positive puncta that normally accumulated in
the presence of Torin1 and baf A1 in ATG4A/B DKO cells.
We then determined that expression of ATG4D alone was
sufficient for priming and lipidation of GABARAPL1 and
GABARAPL2, since ATG4A/B/C triple knockout (TKO)
HeLa cells generated by CRISPR-Cas9 (Figure S9A) also
retained the ability to form lipidated GABARAPL1 and
GABARAPL2 (Figure S9B) and GABARAPL1-positive
puncta in response to treatment (Figure S9C).
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Figure 7. Additional loss of ATG4A in ATG4B KO cells only partially further reduces GABARAP subfamily priming and does not prevent rescue of autophagy by pre-primed
LC3/GABARAP. (a) HeLa control, ATG4B KO and different ATG4A/B double knockout (DKO) clones were treated for 3 h with DMSO or 250 nM Torin1 + 10 nM baf A1 prior to
lysis and western blot analysis. See also Figure S6A for analysis of the same clones by immunocytochemistry of endogenous GABARAPL1. (b) HeLa control, ATG4B KO and
ATG4A/B DKO (c25) were transiently transfected with 3xFLAG-GABARAPL2-GFP. After 24 h, cells were treated for 3 h with DMSO or 250 nM Torin1 + 10 nM baf A1 prior to
lysis and western blotting. 3xFLAG-GABARAPL2-GFP was detected using anti-FLAG antibody. (c) HeLa cells stably transduced with GFP-GABARAPL1-G116 (Control and
ATG4A/B DKO c25) and GFP-LC3B-G120 (ATG4A/B DKO c25) were treated for 3 h with DMSO or 250 nM Torin1 + 10 nM baf A1 prior to fixation and immunocytochemistry to
reveal endogenous SQSTM1 and LAMP1 localization. Scale bar: 10 µm. See also Figure S6B for immunocytochemistry of untransduced cells. (d) Untransduced and stably-
transduced HeLa control and ATG4A/B DKO (c25) cells were assessed for SQSTM1 protein level by western blotting, 48 h after transfection with siRNA targeting RLUC as
a negative control (lanes without +), or EGFP (lanes with +). GFP-LC3B-G120 and GFP-GABARAPL1-G116 were detected using anti-GFP antibody. (e) HeLa ATG4A/B DKO (c25)
cells stably expressing GFP-LC3B-G120 were transfected with siRNA targeting RLUC (negative control), ATG3, ATG7 or GFP (positive control). After 48 h, cells were lysed and
subject to western blot analysis to assess SQSTM1 protein level. GFP-LC3B-G120 was detected using anti-GFP antibody.
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Figure 8. All ATG4 isoforms contribute to GABARAPL1 and GABARAPL2 priming and lipidation independently of CASP3 expression. (a) HeLa control, ATG4B KO and
ATG4A/B DKO (c25) cells transfected with siRNA targeting ATG4C, ATG4D or RLUC (negative control) were treated for 3 h with DMSO or 250 nM Torin1 + 10 nM baf A1
prior to lysis and western blot analysis. (b) Immunocytochemistry of endogenous GABARAPL1 (in green, with Hoechst staining shown in blue) in HeLa ATG4A/B DKO
(c25) cells treated for 3 h with DMSO or 250 nM Torin1 + 10 nM baf A1, after transfection with siRNA against RLUC (negative control) or ATG4C + ATG4D. Scale bar:
10 µm. (c) HeLa control, ATG4B KO, ATG4A/B DKO (c25) and ATG4A/B/C triple knockout (TKO, c22) cells were transfected with siRNA against either RLUC or ATG4D prior
to transfection with 3xFLAG-GABARAPL2-GFP. Cells were treated for 3 h with DMSO or 250 nM Torin1 + 10 nM baf A1 prior to lysis and western blot analysis. See also
Figures S9A-C for additional characterization of HeLa ATG4/A/B/C TKO cells. (d) Western blotting of HeLa control, ATG4A/B DKO (c25) and ATG4A/B/C TKO (c22) cell
lysates following siRNA knockdown of CASP3 or ATG4D. Cells were treated for 3 h with DMSO or 250 nM Torin1 + 10 nM baf A1 prior to lysis.
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To observe the effect of loss of each individual
ATG4 isoform on GABARAPL2 priming, we expressed
3xFLAG-GABARAPL2-GFP in each of the generated HeLa
cell lines following transfection with siRNA (Figure 8(c)). This
revealed that loss of each additional ATG4 isoform led to
a reduction in priming, but that a complete loss of priming
could only be observed upon loss of all ATG4 isoforms. This
effect could also be observed for endogenous GABARAPL1 in
the same cell lysates, assuming that loss of lipidated
GABARAPL1 in response to treatment was a result of
impaired priming (Figure 8(c)). Together these data show
that all human ATG4 isoforms contribute to the priming of
LC3/GABARAP isoforms, because complete loss of
LC3/GABARAP priming and lipidation in cells could only
be achieved upon loss of all ATG4 isoforms.
Because CASP3 promotes ATG4D activity in vitro [18], we
performed knockdown of CASP3 by RNAi to determine
whether the residual activity of ATG4C and ATG4D detected
in HeLa cells lacking ATG4A/B was dependent on
CASP3 expression (Figure 8(d)). Despite efficient knockdown,
we could not detect a reduction in treatment-induced
GABARAPL1 or GABARAPL2 lipidation caused by CASP3
suppression in ATG4A/B DKO and ATG4A/B/C TKO cells, in
contrast to knockdown of ATG4D. Therefore, the residual
priming activity of ATG4C and ATG4D detected in HeLa
cells lacking ATG4A/B does not appear to be dependent on
CASP3 expression.
Delipidation by all ATG4 isoforms is not essential for
autophagosome-lysosome fusion or preventing LC3/
GABARAP mislocalization.
Finally, we decided to determine if delipidation by any ATG4
isoform plays an important role in aspects of autophagy
beyond LC3/GABARAP recycling. Since we already estab-
lished that ATG4A/B-mediated delipidation is not required
for autophagosome closure and lysosome fusion when primed
LC3/GABARAP is expressed at high levels (Figures 6 and 7(c,
d)), we decided to investigate the consequences of further
depletion of ATG4C and ATG4D in the same scenario.
When 3xFLAG-tagged LC3B-G120 and GABARAPL1-
G116 were expressed in HeLa cells lacking different ATG4
isoforms (Figure 9(a)), we noted that combined loss of ATG4
isoforms did not have a dramatic effect on the bypass con-
struct lipidation levels, despite priming of endogenous
GABARAPL2 being efficiently blocked when all ATG4 iso-
forms were suppressed. This is in stark contrast to the equiva-
lent experiment in yeast, where complete loss of Atg4 activity
results in the entire pool of bypass mutant Atg8 becoming
lipidated [10–12]. Therefore ATG4-mediated delipidation is
not necessary for separate pools of free and lipidated LC3/
GABARAP to exist in mammalian cells, although it must be
noted that this was determined when primed LC3/GABARAP
was overexpressed, and technical limitations prevent us from
establishing whether the same is true at endogenous expres-
sion levels of primed LC3/GABARAP. Nonetheless, we were
unable to identify a particular ATG4 isoform that, when
suppressed, could drastically increase the lipidation levels of
overexpressed bypass mutant LC3/GABARAP.
To determine whether delipidation by any ATG4 isoform
is important for basal autophagy, we monitored endogenous
SQSTM1 protein level in ATG4A/B DKO HeLa cells stably
expressing high levels of GFP-LC3B-G120 following siRNA-
mediated knockdown of ATG4C and ATG4D (Figure 9(b,c)).
As described above, stable expression of CMV promoter-
driven GFP-LC3B-G120 in ATG4A/B DKO HeLa cells effi-
ciently rescues the defect in endogenous SQSTM1 turnover.
When quantified from 4 experiments (Figure 9(c), represen-
tative experiment shown in Figure 9(b)), loss of ATG4A/B
resulted in a 5.23 ± 0.95 (mean ± SEM) fold increase in basal
SQSTM1 protein level relative to wild-type control cells
(P < 0.0001). Upon stable expression of GFP-LC3B-G120 in
ATG4A/B DKO cells, SQSTM1 protein reverted to a level that
was not significantly different to wild-type cells (1.39 ± 0.12,
P = 0.890). Knockdown of the rescue construct using siRNA
targeting GFP dramatically increased SQSTM1 protein level to
3.80 ± 0.16 (P < 0.0001, versus SQSTM1 level of 1.39 ± 0.12 in
equivalent RLUC siRNA-transfected cells), signifying
a disruption in autophagy. In contrast, levels of SQSTM1
upon knockdown of ATG4C (1.43 ± 0.16) or ATG4D
(1.86 ± 0.13) alone were not significantly raised (P > 0.999
and P = 0.702 respectively, versus equivalent RLUC siRNA-
transfected cells). Only upon combined knockdown of
ATG4C and ATG4D was there a mild increase in SQSTM1
level (2.30 ± 0.16, P = 0.0337 versus equivalent RLUC siRNA-
transfected cells) and this was substantially less that the raised
level of SQSTM1 upon GFP knockdown (P = 0.0002,
SQSTM1 level of 3.80 ± 0.16). From this, we conclude that
delipidation by ATG4 isoforms is not essential for basal
autophagy when primed LC3B is overexpressed. If the oppo-
site were true, we would expect to observe a much more
dramatic increase in SQSTM1 level upon loss of all ATG4
isoforms in cells stably expressing GFP-LC3B-G120, e.g. simi-
lar to the effect of GFP knockdown.
We also examined the localization of endogenous SQSTM1
in response to Torin1 and baf A1 treatment in HeLa ATG4A/
B DKO cells stably expressing GFP-LC3B-G120 following
knockdown of ATG4C and ATG4D (Figure 9(d)). This
revealed that GFP- and SQSTM1 double-positive structures
can accumulate in response to treatment and localize to
LAMP1-positive lysosomes despite loss of all ATG4 delipida-
tion activity, overall suggesting that delipidation by ATG4
isoforms is not functionally required for autophagosome-
lysosome fusion.
Lastly, we decided to determine whether ATG4-mediated
delipidation was necessary to prevent mislocalization of LC3/
GABARAP, since this is known to be an important function
of Atg4 in yeast [10–12]. We assessed the basal localization of
GFP-LC3B-G120 and GFP-GABARAPL1-G116 stably
expressed at high levels in wild type HeLa cells compared to
cells lacking all ATG4 isoforms (Figure S10). Upon loss of
ATG4-mediated delipidation, we were unable to detect any
change in the localization of GFP-LC3B-G120 or GFP-
GABARAPL1-G116 in relation to the endoplasmic reticulum,
early endosomes, Golgi or lysosomes. We noted a partial
Golgi localization of GFP-GABARAPL1-G116, but this was
also observed in HeLa control cells and was therefore unre-
lated to delipidation.
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Figure 9. Delipidation by ATG4 isoforms is not essential for autophagy of SQSTM1 upon high expression of pre-primed LC3B. (a) HeLa control, ATG4B KO, ATG4A/B
DKO (c25) and ATG4A/B/C triple knockout (TKO, c22) were transfected with siRNA against either RLUC or ATG4D prior to transfection with 3xFLAG-LC3B-G120 or
3xFLAG-GABARAPL1-G116. Cells were treated for 3 h with DMSO or 250 nM Torin1 + 10 nM baf A1 prior to lysis and western blot analysis. Anti-FLAG antibody was
used to assess the lipidation status of 3xFLAG-LC3B-G120 and 3xFLAG-GABARAPL1-G116. (b) HeLa control, ATG4A/B DKO (c25) and ATG4A/B DKO (c25) cells stably
expressing GFP-LC3B-G120 were transfected with combinations of siRNA targeting RLUC (negative control) ATG4C, ATG4D or GFP (positive control) prior to lysis and
western blot analysis to assess the impact of knockdown on basal SQSTM1 protein level. (c) Quantification of SQSTM1 protein level normalized to VCL protein level
from knockdown experiments represented in Figure 9(b). Bars indicate mean and error bars show standard deviation (n = 4 independent experiments). ****
P ≤ 0.0001, *** P ≤ 0.001, * P ≤ 0.05, n.s. P > 0.05 (Sidak’s multiple comparison test). (d) Immunocytochemistry of endogenous SQSTM1 and LAMP1 in HeLa ATG4A/B
DKO (c25) cells stably expressing GFP-LC3B-G120 and transfected with siRNA targeting RLUC or ATG4C + ATG4D. Cells were treated for 3 h with DMSO or 250 nM
Torin1 + 10 nM baf A1 for 3 h prior to fixation and staining. Yellow boxes show region-of-interest in the Torin1 + baf A1-treated condition that is enlarged in the
panels below. Scale bar: 10 µm.
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Together we conclude that while all ATG4 isoforms con-
tribute to the essential priming of LC3/GABARAP, delipida-
tion by ATG4 isoforms (when primed LC3/GABARAP supply
is plentiful) does not play a critical functional role in autop-
hagosome-lysosome fusion and preventing LC3/GABARAP
mislocalization in human cells.
Discussion
Determining Atg gene isoform redundancy is of crucial
importance for understanding the effect of autophagy on
mammalian development. It is also an important considera-
tion in the design and validation of novel therapeutic strate-
gies for modulating autophagy. In the human autophagy
LC3–PE conjugation system, there are seven LC3/GABARAP
isoforms that are processed by four ATG4 isoforms. However,
the requirement of ATG4 isoforms for processing of LC3/
GABARAP isoforms in human cells has remained uncharac-
terized to date. Previous reports into ATG4 function have
been limited to the study of individual ATG4 isoforms or
performed using recombinant proteins or ectopic gene over-
expression. The recent development of CRISPR-Cas9 technol-
ogy for genome editing has greatly accelerated the ability to
perform loss-of-function studies of combinations of endogen-
ous genes in cells. This approach was recently used to dissect
LC3/GABARAP isoform function [14], and we have now
adopted a similar strategy to determine the redundancy of
ATG4 isoforms in autophagy.
By characterizing ATG4B KO cells, we found that ATG4B
was required for the priming of most LC3 subfamily isoforms
(including LC3B and LC3C) but a reduced level of priming of
GABARAP subfamily isoforms could still occur in ATG4B-
deficient cells. Using this cell model in combination with
biochemical assays and expression of mutant LC3/
GABARAP constructs, we were also able to determine the
relative SDS-PAGE migration of all forms of human LC3/
GABARAP, building on previous discoveries [23]. Based on
in vitro data, we initially predicted that all LC3/GABARAP
processing would be executed by ATG4A and ATG4B under
basal and autophagy-induced cellular conditions. As such, we
were surprised that combined loss of ATG4A/B did not
appear have a major effect on endogenous GABARAPL1/L2
processing compared to loss of ATG4B alone. This led to our
discovery that ATG4C and ATG4D also play a role in cells,
since loss of all ATG4 isoforms was required to completely
block the processing of all LC3/GABARAP isoforms.
Importantly, the remaining processing activity in ATG4A/B
DKO and ATG4A/B/C TKO cells was not affected by
a reduction in CASP3 expression, despite ATG4C and
ATG4D being reported to have little detectable processing
activity in vitro unless activated by CASP3 [16,18]. It is
important to note that in our study, we did not address
whether induction of CASP3 activity could enhance the
remaining endogenous ATG4D activity in ATG4A/B/C TKO
cells, as might be predicted based on previous data [18]. There
are several factors that could potentially contribute to the
disparity between in vitro LC3/GABARAP processing and
endogenous processing in cells. These include differences in
protease and substrate concentration, reaction time, post-
translational modifications, and the effect of protein tags in
synthetic constructs. Our data is consistent with ATG4B being
the functionally dominant isoform since its loss results in
a strong autophagy and LC3/GABARAP processing defect,
but contributions to LC3/GABARAP lipidation by all other
ATG4 isoforms could nonetheless be detected upon loss of
ATG4B. We suggest that the broad redundancy of ATG4
isoforms might explain the viability of ATG4B-deficient
mice [19] in contrast to mice lacking ATG3 [20]. Following
submission of our article, a related study reported using
CRISPR-Cas9 to generate HEK293 cells lacking all four
ATG4 isoforms [29]. Interestingly, it was shown that rescue
of these cells with ectopic ATG4C or ATG4D could restore
mild lipidation of GABARAPL1 [29], which is consistent with
our data showing broad ATG4 isoform redundancy in
GABARAP subfamily priming using a sequential knockout/
knockdown strategy.
Our study is the first of its kind to begin addressing the key
question of whether ATG4-mediated delipidation of LC3/
GABARAP plays an essential role in mammalian autophagy.
We discovered that expressing high levels of primed LC3B or
GABARAPL1 in cells lacking ATG4A/B could restore the defect
in autophagic SQSTM1 degradation. This suggests that the
autophagy defect in ATG4A/B-deficient cells arises due to an
insufficient supply of primed LC3/GABARAP. Interestingly,
rescue of ATG4A/B DKO cells with reduced levels of primed
LC3B or GABARAPL1 driven by the PGK promoter was not
sufficient to restore autophagy. This suggests that delipidation
may be important for LC3/GABARAP recycling. Alternatively, it
could be that factors unrelated to delipidation prevent lower
expression of a single primed LC3/GABARAP isoform from
being to able to rescue the autophagy defect of ATG4A/B DKO
cells, such as: competition of bypass mutants with endogenous
pro-LC3/GABARAP, insufficient expression levels of the total
pool of primed LC3/GABARAP (which would normally consist
of up to seven isoforms in wild-type cells), and possible non-
redundant functions of single LC3/GABARAP isoforms that
might only be apparent at low expression levels. Technical
challenges prevent us from being able to generate a model
addressing the role of delipidation while controlling for these
other factors (e.g. ATG4 KO cells expressing endogenous levels
of all primed LC3/GABARAP isoforms that are resistant to
known destabilizing effects of ATG4B loss, lacking all endogen-
ous pro-LC3/GABARAP). Therefore, extensive further studies
are necessary to understand the contrasting results observed
when using different expression levels of LC3/GABARAP bypass
mutants in our ATG4A/B DKO cell rescue experiments.
We further suppressed the function of ATG4C and
ATG4D in ATG4A/B DKO cells expressing high levels of
GFP-LC3B-G120 to determine if remaining ATG4 isoforms
played an essential role in delipidation during autophagy,
independent of any possible recycling function. We could
only observe a relatively modest increase in basal SQSTM1
level for cells stably expressing active LC3B when all ATG4
isoforms were lost. It is possible that this mild effect could be
related to differences in endogenous GABARAP subfamily
isoform function rather than delipidation, since cells lacking
all ATG4 isoforms show a complete absence of primed endo-
genous LC3/GABARAP compared to ATG4A/B DKO cells
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that possess some endogenous GABARAP isoform function.
Further, we could observe evidence of autophagosome-
lysosome fusion in cells lacking delipidation by all ATG4
isoforms. Therefore, our data suggest that delipidation by
ATG4 isoforms is not required for autophagy in mammalian
cells aside from any potential role in primed LC3/GABARAP
supply. It could be the case that other enzymes exist that can
remove LC3/GABARAP from membranes, or alternatively the
removal of LC3/GABARAP from the surface of autophago-
somes might not be required for autophagy to progress.
Although it is well established that ATG4 can cleave lipidated
LC3 in vitro [9,24] and it has been suggested that very little LC3
is detected on the outer membrane of autolysosomes [30,31],
there is little experimental data to link these observations and
directly implicate ATG4 in the delipidation of LC3 in vivo. There
are technical challenges associated with obtaining such evidence.
It has long been known that overexpression of catalytically-
inactive ATG4B in cells is sufficient to impair LC3 lipidation
through binding and sequestering free LC3 [32]. Therefore it can
be presumed that any effects of ATG4B depletion on the locali-
zation or amount of lipidated LC3 may not necessarily be
dependent on ATG4B activity. Recent research has uncovered
at least two distinct LIR-dependent binding interactions between
ATG4 and LC3 [25,33]. These could serve as additional non-
catalytic mechanisms by which ATG4 could negatively regulate
LC3 lipidation, however mutations that disrupt these interac-
tions also severely impede the catalytic activity of ATG4 [25,33].
Consequently, it is currently not possible to distinguish between
catalytic and non-catalytic events mediated by ATG4 that occur
after LC3/GABARAP priming, since one mechanism cannot yet
be experimentally perturbed without affecting the other. Post-
translational modifications add a further layer of complexity to
the regulation of LC3 processing by ATG4 in vivo. We and
others have recently described a mechanism by which the
upstream kinase ULK1 (Atg1 in yeast) can phosphorylate
ATG4B and inhibit both its activity and binding affinity towards
LC3 in cells [21,34]. Combined with our findings, these insights
should lead to a re-assessment of the role of ATG4 downstream
of LC3/GABARAP priming, with the ultimate aim to distinguish
between binding and delipidation effects while accounting for
the contributions of different ATG4 and LC3/GABARAP
isoforms.
Our study has uncovered important technical considerations
for future studies of ATG4 and LC3/GABARAP. Firstly, we
found that levels of lipidated LC3/GABARAP detected by wes-
tern blot could be underestimated due to instability arising from
ATG4 activity in cell lysates. When endogenous or overex-
pressed ATG4 is present in cell lysates, it is capable of converting
pro- or lipidated LC3/GABARAP to the free form. This phe-
nomenon originally resulted in us coming to the false conclusion
that lipidated GABARAP isoforms were more abundant in
ATG4B-deficient cells, when this was actually an artifact arising
from higher ATG4 activity in the lysates of wild-type cells
compared to ATG4B KO cells. Therefore when studying LC3/
GABARAP lipidation in cells by western blotting it is recom-
mended to include NEM or a denaturant in the lysis buffer in
order to immediately inactivate ATG4 isoforms following lysis
and thus avoid detecting non-physiological effects on LC3/
GABARAP processing. Secondly, we confirm a previous study
reporting that human pro-LC3B has a migration rate similar to
LC3B-II in SDS-PAGE [23] by demonstrating that this is true for
endogenous LC3B in human cells completely lacking endogen-
ous ATG4B expression. Therefore it is very important to distin-
guish between pro- and lipidated LC3B when assessing LC3B
status under experimental conditions where ATG4 activity
might be affected.
In conclusion, our study answers a fundamental question
of mammalian autophagy in regards to the degree of genetic
redundancy in the LC3–PE conjugation system. The discovery
that ATG4B is the main human isoform but all other ATG4
isoforms broadly contribute to LC3/GABARAP processing in
cells will be useful for designing autophagy inhibitors and
predicting the effects of ATG4 perturbation in vivo. It will
also provide a basis for understanding how post-translational
modifications of ATG4 affect mammalian autophagy. Finally,
our insights into human autophagy functions that do not
require ATG4-mediated delipidation will inform future stu-
dies with the aim of specifically monitoring this elusive reac-
tion in cells.
Materials and methods
Cell culture
HAP1 control (Horizon Genomics, C631) and HAP1 ATG4B
KO cells (Horizon Genomics, HZGHC001241c011) were grown
in IMDM containing 25 mM HEPES and L-Glutamine
(ThermoFisher Scientific, 12440061) supplemented with
Penicillin-Streptomycin (ThermoFisher Scientific, 15140122;
100 U/ml each) and 10% heat-inactivated FBS (ThermoFisher
Scientific, 10500064). HeLa and HEK293T cells were grown in
DMEM high glucose with GlutaMax and 1 mM pyruvate
(ThermoFisher Scientific, 31966021), penicillin-streptomycin
(100 U/ml) and 10% FBS (ThermoFisher Scientific, 10270106).
All cells were maintained at 37°C, 5% CO2 and passaged at
a dilution of 1:5–1:30 every 2–3 days. Cell line authentication
performed by Eurofins was used to confirm the HeLa identity of
main cell lines used in this study (HeLa control, ATG4B KO,
ATG4A/B DKO c25, ATG4A/B/C TKO c22).
Plasmid transfection
Quantities listed are per well for cells grown in 12-well plate
format, and were scaled according to volume of growth med-
ium used in other formats. HAP1 cells were transfected using
Polyethyleneimine ‘MAX’ (Polysciences, 24765; stock dis-
solved at 1 mg/ml in sterile water and filter sterilized) at
3 µg per 1 µg of DNA, and 1 µg total DNA per 1 ml of growth
medium. Mixtures of DNA and transfection reagent were
diluted in 100 µl of IMDM without supplements, incubated
for 15 min at room temperature, and then added directly to
cells grown in complete IMDM. Cells were returned to incu-
bator and medium was replaced after 4 h. HeLa cells were
transfected with 250 ng DNA using 1.5 µl jetPRIME reagent
(Polyplus-transfection, 114–15) and 50 µl jetPRIME buffer per
1 ml of growth medium. Experiments were performed at 24 h
post-transfection.
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Generation of knockout cell lines using CRISPR-Cas9
Gene-specific sgRNA sequences for human ATG4 isoforms were
identified using Sanger CRISPR Finder tool (http://www.sanger.
ac.uk/htgt/wge/find_crisprs) [35]. Sequences were chosen that
targeted an early constitutive coding exon or residues close to
the catalytic cysteine, and had the lowest possible probability of
off-target cleavage in other gene regions. Oligonucleotides corre-
sponding to desired guide sequences (listed in Table S1) were
phosphorylated, annealed and cloned into BbsI-digested pSpCas9
(BB)-2A-Puro (PX459) V2.0 (Addgene, 62988; Zhang lab) and
delivered by transient transfection to generate knockout HeLa cell
lines [36]. HeLa cells grown in 24-well plate format were trans-
fected with 250–500 ng of DNA per well using PEI or jetPRIME.
After 24 h, transfected cells were enriched by selection with 1 µg/
ml puromycin for 2–3 days, following which puromycin was
removed. Cells were then transferred to 10 cm dishes to recover
for several days. For generation of HeLa ATG4A/B DKO and
ATG4A/B/C TKO cells, the procedure was repeated 3 times in
an attempt to increase the efficiency of gene disruption on multi-
ple alleles. Single-cell clones were then isolated by limiting dilution
in 96-well plates and grown for 2 weeks. Clones were screened for
loss of target protein expression by western blot after expansion
into 12-well plates. Positive clones were expanded and further
validated by sequencing PCR-amplified genomic DNA of the
target locus to confirm gene editing of all detected alleles. Loss
of plasmid expression was demonstrated by confirming that
clones had regained sensitivity to puromycin treatment. To gen-
erate HeLa control cells, unmodified HeLa cells were transfected
with PX459 encoding a non-targeting sgRNA [37], selected with
puromycin for 2 days, and then passaged as a pool for at least
three weeks prior to use in experiments.
Lentiviral production and stable cell line generation
HEK293T cells grown in a 6-well plate format were co-
transfected with 900 ng psPAX2 (Addgene, 12260; Trono lab),
100 ng pMD2.G (Addgene, 12259; Trono lab) and 1 µg of
transfer plasmid per well using X-tremeGENE HP (Roche,
6366244001) at 2 µl per µg of total DNA. At 18 h post-
transfection, medium was replaced with complete IMDM.
Viral supernatant was harvested at 48 and 72 h post-
transfection, filtered through a 0.22-µm low protein-binding
syringe filter and frozen at −80°C. Target cells seeded at
a medium density in 24-well plates were infected overnight
with 300 µl of filtered viral supernatant containing polybrene
at a final concentration of 8 µg/ml. Cells were selected at 48 h
post-infection with 1 µg/ml puromycin, expanded into 10-cm
dishes and passaged once before puromycin was excluded from
growthmedium. Experiments were performed without puromy-
cin present using pooled populations of transduced cells.
RNA interference
HeLa cells grown in a 12-well format were transfected with a total
of 500 ng MISSION esiRNA (Sigma) per well diluted in 100 µl
jetPRIME buffer using 3 µl of jetPRIME reagent. Thismixture was
added directly to 1 ml of growth medium present in the well. In
experiments where 2 targets were depleted simultaneously, the
amount of esiRNA against each target was halved to keep the
total amount of esiRNA constant. In these experiments, negative
control esiRNA targeting RLUC was used to keep the esiRNA
dosage constant in samples where only one target was depleted.
Experiments were performed at 48 h after siRNA transfection. In
siRNA experiments involving cDNA transfection, medium was
changed at 24 h following siRNA transfection, and DNA transfec-
tion was subsequently performed as described. Catalog numbers
and targets of esiRNAs are as follows: RLUC (Renilla luciferase;
Sigma, EHURLUC), human ATG4C (Sigma, EHU060781),
human ATG4D (Sigma, EHU035721), EGFP (enhanced GFP;
Sigma, EHUEGFP), human CASP3/caspase-3 (Sigma,
EHU085021), human ATG3 (Sigma, EHU015141), human
ATG7 (Sigma, EHU092581).
Antibodies and reagents
Primary antibodies and dilutions used for western blot in this
study were as follows: ATG3 (Abcam, ab108251; 1:1,000), ATG4A
(Cell Signaling Technology, 7613; 1:1,000), ATG4B C terminus
(Cell Signaling Technology, 5299; 1:1,000), ATG4B N terminus
(Sigma, A2981; 1:1,000), ATG4C (Cell Signaling Technology,
5262; 1:200–1:500), ATG4D (Proteintech, 16924–1-AP; 1:1,000),
ATG7 (Abcam, ab52472; 1:2,000), Beta-actin (Sigma, A1978;
1:4,000), CASP3/caspase-3 (Santa Cruz Biotechnology, sc-56053;
1:200), FLAG biotin-conjugated (Sigma, F9291; 1:1,000),
GABARAP (Abgent, AP1821a; 1:1,000), GABARAPL1
(Proteintech, 11010–1-AP; 1:1,000), GABARAPL2 (Abcam,
ab126607; 1:500), GFP (Clontech, 632381; 1:2,000), LAMP1 (BD
Biosciences, 611043; 1:500), LC3A/B (Cell Signaling Technology,
12741; 1:500), LC3B (Sigma, L7542; 1:1,000 was used for LC3B
western blotting unless otherwise stated) and (Cell Signaling
Technology, 3868; 1:1,000 was used for western blotting in
Figure S1B only), MFN2/mitofusin 2 (Abcam, ab56889; 1:500),
SQSTM1/p62 (Sigma, P0067; 1:1,000), PDHA1/pyruvate dehy-
drogenase E1 alpha 1 subunit (Abcam, ab110330; 1:1,000), ubi-
quitin (Santa Cruz Biotechnology, sc-8017; 1:500), ULK1 (Cell
Signaling Technology, 4733; 1:500), p-ULK1 S757/phospho-ULK
1 Ser747 (Cell Signaling Technology, 6888; 1:1,000), VCL/vinculin
(Abcam, ab129002; 1:1,000). Secondary antibodies usedwere: goat
anti-mouse/rabbit IgG HRP (Cell Signaling Technology, 7076/
7074; 1:5,000), IRDye 800CW goat anti-rabbit (LI-COR
Biosciences, 926–32211; 1:15,000 with 0.02% SDS) and IRDye
680LT goat anti-mouse (LI-COR Biosciences, 926–68020;
1:25,000 with 0.02% SDS).
For immunocytochemistry, the following antibodies and
dilutions were used: CANX/calnexin (BD Biosciences, 610523;
1:50), EEA1 (BD Biosciences, 610456; 1:200), GABARAPL1
(Proteintech, 11010–1-AP; 1:200), GFP (Abcam, ab290; 1:500),
GOLGA2/GM130 (BD Biosciences, 610822; 1:500), LAMP1 (BD
Biosciences, 555798; 1:1,000), LC3B (Cell Signaling Technology,
3868; 1:200), SQSTM1/p62 (Sigma, P0067; 1:1,000). Secondary
fluorescent antibodies used were: Alexa Fluor 488/568 goat anti-
rabbit IgG (H + L; ThermoFisher Scientific, A-11008/11011;
1:400), Alexa Fluor 647 goat anti-mouse IgG (H + L;
ThermoFisher Scientific, A-21235; 1:400).
Torin1 (Merck-Millipore, 475991) was dissolved in DMSO
at a final stock concentration of 250 µM. Bafilomycin A1 from
Streptomyces griseus (Sigma, B1793) was dissolved in DMSO
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at a final stock concentration of 10 µM. Recombinant GST-
ATG4B WT was described previously [38]. Other reagents
were as follows: PLD/phospholipase D from Streptomyces
chromofuscus (Sigma, P0065), EBSS containing calcium and
magnesium (ThermoFisher Scientific, 24010–043). For the
protease protection assay, Trypsin from porcine pancreas
was used (Sigma, T4799).
Plasmids and cloning
Expression constructs of tagged WT and mutant human LC3/
GABARAP isoforms were generated using Gateway cloning
technology (Life Technologies). Entry clones were first generated
by PCR using complementary or mutagenic primers with attB
sequence overhangs (listed in Table S2) followed by recombina-
tion with pDONR223 using BP clonase II enzyme mix
(ThermoFisher Scientific, 11789020) [39]. To generate
N-terminal 3xFLAG-tagged constructs, entry clones containing
stop codons were recombined with the destination vector
pCMV-tripleFLAG-Gateway [40] using LR clonase II enzyme
mix (ThermoFisher Scientific, 11791020). To make transient
expression constructs of GFP-LC3/GABARAP, pDEST-CMV
-N-EGFP was used as the destination vector. For generating
3xFLAG-ATG8-EGFP double-tagged constructs, entry clones
lacking stop codons were recombined with pDEST-CMV
-3xFLAG-gateway-EGFP. To generate lentiviral transfer vectors
for the production of cell lines stably expressing CMV promoter-
driven GFP-tagged ATG8 isoforms, entry clones containing stop
codons were recombined with pLVpuro-CMV-N-EGFP.
Novel destination vector constructs were generated as follows.
EGFP was PCR amplified from pEAK13-EGFP using the primers
5ʹ-GFP-Kpn1 (5ʹ-acgtaGGTACCGCCACCATGGTGAGCAAG
GGCGAGGAGCTGTTC-3ʹ) and 3ʹ-GFP-HindIII (5ʹ-acgtaAA
GCTTCTTGTACAGCTCGT CCATG CCGAG AGTGATC-3ʹ),
cut and ligated into pCMV-tripleFLAG-Gateway using KpnI and
HindIII enzymes to generate pCMV-EGFP-gateway. A portion of
the CMV promoter and EGFP was then PCR amplified using the
primers 5ʹ-CMV-SacI (5ʹ-gacGAGCTCGTTTAGTGAACCGTC-
3ʹ) and 3ʹ-EGFP-SacI (5ʹ-gacGAGCTCGTCCATGCCGTGA
GTGATC-3ʹ), cut and ligated into Gateway® pcDNA™-DEST53
(ThermoFisher Scientific, 12288015) using SacI digestion to gen-
erate pDEST-CMV-N-EGFP. The EGFP tag and gateway cassette
portion of pDEST-CMV-N-EGFP was PCR amplified using the
primers 5ʹ-EGFP-NheIPacIXbaI (5ʹ-GACGCTAGCTTAATTAA
GACTCTAGAGCCACCATGGTGAGCAAG-3ʹ) and 3ʹ-attR2-
BstBI (5ʹ-gacTTCGAATCACACCACTTTGTACAAGAAAG-3ʹ)
and cloned into pLV-CMV-y/hNubI-tripleFLAG-linker-
Gateway- PuroR using NheI and BstBI digestion to generate
pLVpuro-CMV-N-EGFP. The gateway cassette and 3ʹ linker
region of Gateway® pcDNA™-DEST47 (ThermoFisher Scientific,
12281010) was PCR amplified using the primers 5ʹ-gateway-
KpnIHpaINheI (5ʹ-GACGGTACCGGCGTTAACGACGCTAG
CGGagttaagcttgatcaaacaagtttg-3ʹ) and 3ʹ-linker-XhoIPmeIPacI
(5ʹ-GACTTAATTAAG CCGGTT TAAACACCGCTC GAGtcta
gatcgaaccactttgtaca-3ʹ) and ligated into pDEST-CMV-N-EGFP
following digestion with KpnI and PacI to generate pDEST-
CMV-polysite. EGFP was PCR amplified from pEAK13-EGFP
using the primers 5ʹ-EGFP-XhoI (5ʹ-GACCTCGAGATGG
TGAGCAAGGGCGAG-3ʹ) and 3ʹ-EGFP-stop-PacI (5ʹ-GAC
TTAATTAATTACTTGTACAGCTCGTCCATG-3ʹ) and ligated
into pDEST-CMV-polysite after digestion with XhoI and PacI to
generate pDEST-CMV-C-EGFP. 3xFLAG-attR1 fragment was
digested from pCMV-tripleFLAG-Gateway and subcloned into
pDEST-CMV-C-EGFP following digestion with KpnI and NotI
to generate pDEST-CMV-3xFLAG-gateway-EGFP.
To generate lentiviral transfer plasmids for the production of
stable cell lines expressing PGK promoter-driven LC3B or
GABARAPL1 mutants, the GFP-LC3/GABARAP coding
sequence was PCR amplified from the respective variant of
pDEST-CMV-N-EGFP and subcloned by restriction digests
between the BamHI and SalI sites of pLenti PGK GFP Puro
(w509-5) (Addgene, 19070; Campeau and Kaufman labs) [41].
These PCRs were performed using the common forward primer
5ʹ-EGFP-BamHI (5ʹ- GACGGATCCGCCACCATGGTGAGC
AAG-3ʹ) and one of the following reverse primers: 3ʹ-LC3B-
G120-SalI (5ʹ- GACgtcgacTTACCCGAACGTCTCCTGG-3ʹ),
3ʹ-LC3B-GA-SalI (5ʹ-GACgtcgacTTACACTGACAATTTCAT
CGCG-3ʹ), 3ʹ-GABARAPL1-G116-SalI (5ʹ-GACgtcgacTTACC
CATAGACACTCTCATCA-3ʹ) or 3ʹ-GABARAPL1-GA-SalI (5ʹ-
GACgtcgacTTATTTCGCATAGACACTCTCATC-3ʹ). All clon-
ing was confirmed by diagnostic restriction enzyme digests and
Sanger sequencing of coding sequences.
Genomic DNA isolation and analysis
Genomic DNA was isolated using NucleoSpin Tissue genomic
DNA purification kit (Macherey-Nagel, 740952) according to
the manufacturer’s protocol for cultured cells. The genomic
locus of interest was PCR-amplified using specific primers
(listed in Table S1) designed using NCBI Primer-BLAST
(https://www.ncbi.nlm.nih.gov/tools/primer-blast) [42] against
relevant regions of reference genome sequence retrieved using
the ‘Table Browser’ function of UCSC Genome Browser
(https://genome.ucsc.edu/cgi-bin/hgTables) [43]. Genomic pri-
mers incorporated attB sequence overhangs to allow subse-
quent gateway cloning of gel-purified PCR product into
pDONR223 using BP Clonase II enzyme mix. The reaction
mix was transformed into bacteria and plasmid DNA was
extracted from overnight cultures of multiple individual clones
and sequenced by Sanger sequencing using M13 F and
R primers. Genotyping results of main CRISPR-modified
clones used in this study are provided in Table S3.
Western blotting
Cells were washed in ice-cold PBS (137 mM NaCl, 2.7 mM KCl,
10 mMNa2HPO4, 1.8 mM KH2PO4, pH 7.4) prior to lysis in NP-
40 lysis buffer (150 mM NaCl, 1% IGEPAL® CA-630/NP-40
substitute [Sigma, I8896], 50 mM Tris-HCl, pH 8.0) containing
protease inhibitors (c0mplete, EDTA-free, Roche, 11873580001)
and 20 mM N-ethylmaleimide (unless otherwise stated) on ice.
Lysates were cleared by centrifugation at 15,200 x g at 4°C and the
resulting pellet was discarded. Protein levels were quantified using
Pierce BCA Protein Assay Kit (ThermoFisher Scientific, 23,225)
and lysates were diluted to approximately equal concentrations
before heating in SDS sample buffer (with final concentration in
the sample of 50 mM Tris-Cl, pH 6.8, 2% SDS, 10% glycerol, 5%
beta-mercaptoethanol, 0.01% bromophenol blue) at 95°C for 5
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min. Equal amounts of sample (typically 25 µg total protein per
lane) were loaded into lanes of a 15-well 4–20%Mini-PROTEAN
TGX Precast Gel or 26-well 4–20% Criterion TGX gel (Bio-Rad)
and run at 115 V constant for 75min or 200 V for 35min. Protein
was transferred to Immobilon-FL PVDF membrane (Merck-
Millipore, IPFL00010) before blocking with 5% skimmed milk
in PBS-T (PBS containing 0.05% Tween® 20 [Sigma, P1379]). The
membrane was probed with primary antibody in blocking buffer
at room temperature for 1 h or overnight at 4°C. After washing
with PBS-T, the membrane was incubated in secondary antibody
in blocking buffer for 1 h at room temperature. Further washes
were carried out before image acquisition on an Odyssey infrared
imaging system (LI-COR Biosciences) or development using EZ-
ECL chemiluminescence detection kit for HRP (Geneflow Ltd,
K1-0172) followed by exposure on an ImageQuant chemilumens-
cent imaging system (GE Healthcare).
PLD bandshift assay
After treatment with compounds, cells were lysed on ice in PLD
assay buffer (150 mM NaCl, 50 mM Tris-HCl, pH 8.0, 5 mM
CaCl2, 1% Triton X-100 [Sigma, X100]) without EDTA or pro-
tease inhibitors, because PLD requires Ca2+ for its activity [44].
Lysates were cleared by centrifugation and then divided into
separate tubes of equal volumes. On ice, PLD was added to
a final concentration of 2.5 units/µl, or GST-ATG4B was added
to a final concentration of 0.1 µg/µl. For negative control sam-
ples, an equivalent volume of PLD assay buffer was added.
Samples were then heated to 37°C for 1 h while an unheated
sample was kept on ice for this duration as a control. The
reaction was stopped by the addition of 5X SDS sample buffer
(250 mM Tris-Cl, pH 6.8, 10% SDS, 50% glycerol, 25% beta-
mercaptoethanol, 0.05% bromophenol blue) to the tube with
immediate boiling at 95°C for 5 min. Equal volumes of sample
were then loaded on a 4–20% gel and assessed by western blot.
Protease-protection assay
Our protease-protection assay was adapted and optimized from
a combination of 2 published protocols [45,46]. Cells were
seeded 24 h prior to transfection in one 10-cm dish per sample.
The day after transfection, cells were treated with Torin1 and baf
A1 for 3 h before harvesting by trypsinization (ThermoFisher
Scientific, 25200056) at 37°C. Trypsin for harvesting was inacti-
vated by resuspending intact cells in pre-warmed complete
growth medium. Cells were then gently centrifuged and washed
once in ice-cold PBS to remove traces of trypsin. Cells were again
centrifuged and resuspended in 0.7 ml of ice-cold homogeniza-
tion buffer (HB: 10 mM HEPES-KOH, pH 7.5, 0.22 M
D-mannitol, 0.07 M sucrose [Sigma, S0389], 1 mM EDTA,
1 mM DTT). All subsequent steps were performed on ice or at
4°C. Cells were ruptured by passing the suspension 10 times
through a 27G needle attached to a 1 ml syringe. Following this,
cells were centrifuged twice at 300 x g and the nuclear pellet was
discarded. Each sample was then divided into 2 tubes and
permeabilized or not permeabilized by addition of 5% Triton
X-100 in HB to a final concentration of 0.5%, or an equivalent
volume of HB. These mixtures were then further subdivided into
3 tubes, one of which had 1 mg/ml trypsin (dissolved fresh in
HB) added to a final concentration of 100 µg/ml, while the other
2 untreated tubes had an equivalent volume of HB added. Two
were then incubated at 37°C for 30 min, while one untreated
tube was kept on ice as a control. To stop the reactions, all tubes
were placed on ice and 5X SDS sample buffer was added, before
immediate boiling at 95°C for 10 min. Equal volumes of sample
were then immediately loaded on 4–20% polyacrylamide gels
and analyzed by western blotting.
Immunocytochemistry and light microscopy
Cells seeded on borosilicate glass coverslips (13-mm diameter,
thickness no. 1.5; VWR, 631–0150) were washed in PBS and
fixed for 12 min at room temperature in 4% paraformaldehyde
in PBS. For imaging fluorescent proteins alone, the coverslips
were then washed, stained with 1 µg/ml Hoechst 33342
(ThermoFisher Scientific, H3570) for 10 min, washed and
mounted onto glass slides using ProLong Diamond mounting
medium (ThermoFisher Scientific, P36970) and cured overnight
at room temperature in the dark. For immunocytochemistry, cells
were permeabilized and fixed a second time in ice cold methanol
at −20°C for 12 min, washed in PBS, quenched in 50 mMNH4Cl
in PBS for 20 min, washed, and incubated in blocking buffer (3%
goat serum [ThermoFisher Scientific, 16210064] in PBS) for 1 h.
Coverslips were transferred to humidified staining boxes and in
incubated overnight at 4°C with 45 µl primary antibody diluted in
blocking buffer. Coverslips were then washed 3 times with PBS for
a total of 10 min, and then incubated with 45 µl secondary anti-
body in blocking buffer containing 1 µg/ml Hoechst 33342 for 1 h
at room temperature, prior to washing and mounting onto slides.
For co-staining experiments, antibodies raised in different species
against different target proteins were incubated simultaneously.
Fixed cells were imaged on a Leica SPE, inverted SPE, SP5 or SP8
confocal laser-scanning microscope using a 63x oil immersion
objective with a numerical aperture (N.A.) of 1.3 (SPE, inverted
SPE) or 1.4 (SP5, SP8) at 400 Hz with sequential channel acquisi-
tion. Laser and gain settings were optimized for the brightest
sample to avoid signal saturation, and the same settings were
used to image all samples within a single experiment. All images
shown are of a single confocal Z-slice. For some confocal micro-
scopy figures, the contrast level was increased in a linear manner
using the ‘Levels’ tool in Adobe Photoshop to improve clarity.
When performed, this adjustment was applied equally and uni-
formly to all experimental conditions and controls.
Transmission electron microscopy
Cells seeded on glass coverslips were first fixed by addition of an
equal volume of double-concentrate fixative solution (3% formal-
dehyde, 0.2% glutaraldehyde in PBS) for 15 min at room tem-
perature. Cells were then fixed a second time in 2% glutaraldehyde
in 0.1 M sodium cacodylate for 15 min. Coverslips were then
rinsed twice in 0.1 M sodium cacodylate and fixed in 1% osmium
tetroxide 1.5% potassium ferrocyanide for 1 h at 4°C. After rinsing
3 times in 0.1M sodium cacodylate, samples were stained with 1%
(w:v) tannic acid in 0.05M sodium cacodylate for 45 min at room
temperature in the dark, before incubation with 1% (w:v) sodium
sulfate in 0.05 M sodium cacodylate. Samples were then dehy-
drated by sequential 5-min incubations in distilled water, followed
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by 70% ethanol (x2), 90% ethanol (x2) and 100% dry ethanol (2x).
Coverslips were then transferred to a 1:1 (v:v) mix of propylene
oxide:TAAB 812 resin (TAAB Laboratories Equipment Ltd,
T024) for 1 h. Samples were transferred again twice to fresh
resin for 1.5 h each time. Coverslips were thenmounted onto pre-
polymerized blocks with a drop of fresh resin and baked overnight
at 60°C. Glass was removed by cooling in liquid nitrogen and 70-
nm ultrathin sections were cut parallel to the growth surface using
a diamond knife and collected on formvar-coated copper slot
grids (Agar Scientific, AGG2525C). Sections were stained with
lead citrate, washed 6 times with distilled water, and air dried
before imaging on a Tecnai Spirit (FEI) with a Morada digital
camera (EMSIS) at 120 kV.
Correlative light and electron microscopy
Stably transduced cells were seeded on a gridded glass coverslip in
a 35-mm cell culture dish (MatTek, P35G-2–14-C-GRID). The
next day, cells were treated with compounds, and MitoTracker
Red cmxROS (Lonza, PA-3017) was added to the growthmedium
at a concentration of 100 nM for the final 45 min of the experi-
ment. Cells were fixed by addition of an equal volume of double-
concentrate fixative solution (3% formaldehyde, 0.2% glutaralde-
hyde, 2 µg/ml Hoechst 33342 in PBS) for 15 min at room tem-
perature. Cells were then washed twice in PBS and left in PBS for
imaging. A cell near the center of the coverslip was imaged on
a Leica inverted SP5 confocal laser scanningmicroscope with DIC
using a 63x numerical aperture 1.4 oil immersion objective.
Z-stacks were acquired at a slice separation of 300 nm and
channels were acquired sequentially for each slice in turn.
A DIC image showing the morphology of the cell and its grid
position was acquired using a 40x objective. After imaging, sam-
ples were fixed a second time with 2% glutaraldehyde 0.1 M
sodium cacodylate for 15 min at room temperature. After wash-
ing, samples were osmium fixed, stained, dehydrated and
embedded as described above for conventional TEM. The same
cell imaged by confocal microscopy was then re-located on the
block face by referring to its grid position and morphology from
the DIC image. The block was trimmed to this region and serial
sections were collected, stained, and imaged by TEM as above.
Light microscopy data were adjusted for clarity in a linear manner
using brightness and contrast tools, prior to being manually
aligned with electron microscopy data using the transform and
layers tools in Adobe Photoshop. DIC images and TEM low
power overview, together with MitoTracker signal and mitochon-
dria ultrastructure, were used as unbiased fiducial markers.
Morphometric analysis of autophagosomes from TEM
images
Olympus iTEM software was used. For each cell, cytoplasm area
was first calculated using a lowmagnification image by outlining
the entire cell using the interpolated polygon tool, measuring
total area, and subtracting the nuclear area. Autophagosomes
were then identified, using higher magnification images, based
on their distinctive morphology of cytoplasmic contents within
membrane-limited compartments. To measure autophagosome
size, the outer limiting membrane of each structure was traced
using the freehand selection tool in 2D.
Densitometry
Protein levels were quantified using the Analyze>Gel function
in FIJI/ImageJ (NIH). The raw unprocessed western blot
image was opened and a box was drawn surrounding the
band of interest. After background subtraction, the histogram
area of the signal of each band was determined and divided by
the corresponding signal of a loading control band (ACTIN or
VCL) from the same gel lane.
Image analysis
Puncta of endogenous LC3B and GABARAPL1 were counted in
an unbiased semi-automated manner using the ‘Find Maxima’
tool in FIJI/ImageJ (NIH), with a noise tolerance value of 150 or
140, respectively. The nuclear region was first excluded from
analysis by inverting the selection of a binary image generated
using the Hoechst channel. Automatically identified puncta were
manually counted and assigned to a parent cell to generate each
data point. Colocalization between SQSTM1 and LAMP1 was
assessed using the Coloc 2 plugin in FIJI. An individual cell was
manually selected as an ROI using the polygon selection tool to
generate each data point.
Statistical analysis
All statistical tests were done using GraphPad Prism.
Unpaired two-tailed t-tests were performed for experiments
comparing two sets of data. For experiments involving the
comparison of multiple sets of data, an ordinary one-way
ANOVA was performed using Sidak’s multiple comparison
post-test to compare relevant pre-defined dataset pairs.
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